We are live on ! Find out more

PolyPid

PYPD

Market cap $103M

5.07 USD

-0.05

0.98%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

5.17

+0.10

1.97%

1 day

-0.98%

5 days

-0.98%

1 month

35.2%

3 months

6.51%

6 months

16.82%

Year to date

16.55%

1 year

50%

5 years

-98.14%

10 years

-99.11%

About: PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Employees: 75

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 75%

Negative 0%

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Q2 Earnings Call Highlights

PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada.

PolyPid Q2 Earnings Call Highlights

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its second quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PolyPid, Azurity sign surgical site infection drug deal

Israeli biotech PolyPid said on Tuesday it had agreed a deal with Azurity Pharmaceuticals to commercialise a drug aimed at preventing surgical ‌site infections in the U.S. and Canada, under which it could receive more than $320 million.

PolyPid, Azurity sign surgical site infection drug deal

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PETACH TIKVA, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has entered into an exclusive commercial partnership agreement (the “Agreement”) with Azurity Pharmaceuticals (“Azurity”), a privately held specialty pharmaceutical company, for the commercialization of D-PLEX100 in the United States and Canada for the prevention of surgical site infections (“SSIs”).

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company's management will participate in investor meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, at the Depot Renaissance Hotel in Minneapolis, MN.

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PolyPid Q1 Earnings Call Highlights

PolyPid NASDAQ: PYPD said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery.

PolyPid Q1 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™